ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Losartan

Also written as “losartan potassium”, “Amlodipine plus Losartan” and “Losartan (COZZAR®)”.

Its studies are mostly in Hypertension · Essential Hypertension · Diabetes Mellitus, Type 2 · Proteinuria · Heart Failure, led by 11 companies.

Drug pageLosartan: every studyMany companies study it; this page follows only the 41 they lead. All 240 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 30, 200541 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only120 open or runningphase 4since Aug 30, 2005Aug 25, 2004none ahead
Hanmi Pharmaceuticalits history only80 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Merckits history only60 open or runningphase 3since Apr 14, 2009Feb 27, 2009none ahead
Torrent Pharmaceuticalsits history only40 open or runningphase 1since Oct 7, 2010Oct 7, 2010none ahead
Hikma Pharmaceuticalsits history only30 open or runningno phasesince Apr 9, 2010Apr 9, 2010none ahead
Laboratorios Silanes S.A. de C.V.its history only20 open or runningphase 3since Jun 8, 2021Jun 8, 2021none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since May 13, 2010May 13, 2010none ahead
Azidus Brasil10 open or runningphase 1since Sep 21, 2012Sep 21, 2012none ahead
InVasc Therapeuticsits history only10 open or runningphase 4since Jan 5, 2011Jan 5, 2011none ahead
Medtronicits history only10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead

Also a collaborator on its studies: Reliance Life Sciences Private.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Azidus Brasil only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2012First study: phase 1 study in Healthy SubjectsFirst studyNCT01692717 · 90 enrolled · Brazil

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
TelmisartanruleBoehringer Ingelheimphase 4132
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The one study Azidus Brasil leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01692717Healthy Subjects · Brazil1CompletedMay 31, 201390

How it is read

Names in the registry

  • “losartan potassium”, 10 entries
  • “Losartan”, 8 entries
  • “Amlodipine plus Losartan”, 5 entries
  • “Losartan (COZZAR®)”, 2 entries
  • “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries

Codes read as this program: MK0954.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.